ArticleEuropean journal of neurology2026
Early Detection of Central Nervous System Involvement in ATTRv Using Multimodal MRI and Cognitive Assessments.
Article in European journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early Detection of Central Nervous System Involvement in ATTRv Using Multimodal MRI and Cognitive Assessments.European journal of neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHereditary Transthyretin Amyloidosis with polyneuropathy (ATTRv-PN) is an autosomal dominant disorder characterized by TTR gene mutations, causing amyloid fibril deposition in peripheral nerves. Significant CNS involvement has been noted, emphasizing the necessity for advanced neuroimaging tools for early detection of CNS damage in ATTRv.
methodsComprehensive clinical assessments and multimodal MRI techniques, including FreeSurfer, TBSS and microbleed analysis, were utilized. The cohorts comprised 30 symptomatic patients (ATTRv-PN), 19 presymptomatic patients (pre-ATTRv-PN), classified based on neuropathic signs, and 44 age- and sex-matched controls. For cognitive assessment, we utilized the Addenbrooke's Cognitive Examination-Revised.
resultsThe ATTRv-PN group had an average age of 51 years, while the pre-ATTRv-PN group averaged 41 years, with a sex ratio of 35% men to 65% women. Symptomatic patients experienced an average disease duration of 5 years, predominantly featuring the p.Val50Met genotype (73%). Brain imaging showed diffuse subcortical white matter alterations in ATTRv-PN, while cortical thinning and microbleeds were infrequent. Cognitive assessments revealed significant differences, with symptomatic scoring lower in memory and verbal fluency than presymptomatic.
conclusionATTRv-PN involves cerebral white matter microstructural damage from early stages. Multimodal MRI serves as an accurate, non-invasive tool for detecting CNS damage, improving our understanding of the disease spectrum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.